Back HCV Prevention

IAS 2015: PrEP and the Risk of Hepatitis C Virus Infection [VIDEO]

 Are gay and bisexual men who take Truvada for HIV pre-exposure prophylaxis (PrEP) at greater risk for sexually transmitted hepatitis C virus (HCV) infection? Experts discussed this issue and others at a media briefing on HIV and hepatitis coinfection at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last month in Vancouver.

alt

Read more:

HIV-Negative Gay Men May Be Susceptible to Sexually Transmitted Hepatitis C

Several studies have shown that hepatitis C virus (HCV) can be sexually transmitted among HIV-positive men who have sex with men, but HIV-negative gay and bisexual men may be at risk as well if they share similar risk factors, according to a report in the June 2015 Journal of Viral Hepatitis.

alt

Read more:

EASL 2015: Reinfection after HCV Cure - Long-term Support Needed for People Who Have Injected Drugs

Reinfection rates after a hepatitis C cure among people who inject drugs, as well as past drug users, are relatively low, according to findings from studies from Norway and Canada presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress in Vienna in April. The findings suggest that current and former injection drug users who have been cured of hepatitis C require ongoing support to remain free of HCV, but also indicate that fears of a high rate of reinfection should not be used as a reason to withhold hepatitis C treatment from people who inject drugs.

alt

Read more:

EASL 2015: Hepatitis C Treatment Could Cut HCV Transmission Among UK Gay Men in Half

Access to more effective hepatitis C treatment could reduce new infections among men who have sex with men in the United Kingdom by half over the next decade, according to a mathematical modeling study presented at the European Association for the Study of the Liver (EASL) International Liver Congress in Vienna in April.

alt

Read more:

EASL 2015: Civacir Immune Globulin May Help Prevent HCV Reinfection after Liver Transplant

Civacir, a hepatitis C immune globulin or antibody product, reduced the likelihood of hepatitis C virus infecting the new liver graft after transplantation in patients who were receiving but had not yet completed antiviral treatment, according to preliminary study findings presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.

alt

Read more: